{"Clinical Trial ID": "NCT01094184", "Intervention": ["INTERVENTION 1:", "Bevacizumab 10 mg/kg Q2W", "Participants received bevacizumab at a dose of 10 mg/kg Q2W for intravenous infusion with paclitaxel Q1W or docetaxel Q3W at the discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent.", "INTERVENTION 2:", "Bevacizumab 15 mg/kg Q3W", "Participants were given bevacizumab at a dose of 15 mg/kg Q3W intravenously with paclitaxel Q1W or docetaxel Q3W at the discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent."], "Eligibility": ["Incorporation criteria:", "A triple negative adenocarcinoma (estrogen, progesterone and HER-2 negative) confirmed histologically in pre- and post-menopausal women with measurable or non-measurable metastatic disease", "\u2022 Participant who, in the opinion of the investigator, needs combined treatment for his or her illness", "Life expectancy greater than or equal to (>/=)12 weeks", "- Exclusion criteria:", "Previous chemotherapy for metastatic breast cancer", "Participants in radiotherapy for the treatment of metastatic diseases (except for the relief of metastatic bone pain)", "\u2022 Major surgery or significant traumatic injury within 28 days prior to registration or anticipation of major surgery during study treatment"], "Results": ["Performance measures:", "Change from baseline in functional assessment of breast cancer (FACT-B) at Cycle 2", "The high score is a better QoL. All measurements in a single article range from 0='Not at all' to 4='Very much'. The total possible score ranged from 0 to 144. The high score represents a better QoL.", "Duration: Baseline, cycle 2 (cycle length = 2 and 3 weeks)", "Results 1:", "- Arm/group title: Bevacizumab 10 mg/kg Q2W", "- Arm/group description: Participants received bevacizumab at a dose of 10 mg/kg Q2W for intravenous infusion with paclitaxel Q1W or docetaxel Q3W at the discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent.", "Total number of participants analysed: 31", "Average (standard deviation)", "Unit of measurement: units on a reference scale: 31 participants", "98.3 (21.342)", "Change in cycle 2: 25 participants", "5.83 (17.027)", "Results 2:", "- Arm/group title: Bevacizumab 15 mg/kg Q3W", "- Arm/group description: Participants received bevacizumab at a dose of 15 mg/kg Q3W for intravenous infusion with paclitaxel Q1W or docetaxel Q3W at the discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent.", "Total number of participants analysed: 12", "Average (standard deviation)", "Unit of measurement: units on a reference scale: 12 participants", "102.21 (21.036)", "Change in cycle 2: 6 participants", "-2.48 (14.697)"], "Adverse Events": ["Undesirable Events 1:", "Total: 15/36 (41.67%)", "Neutropenia * 0/36 (0.00 %)", "Diarrhoea * 1/36 (2.78%)", "Small intestinal perforation * 0/36 (0.00 %)", "Dermatitis of the catheter site * 0/36 (0.00 %)", "* 1/36 (2.78%)", "Fatigue * 1/36 (2.78%)", "Pain * 1/36 (2.78%)", "Pyrexia * 1/36 (2.78%)", "Hypersensitivity * 1/36 (2.78%)", "* 1/36 (2.78%)", "Gastroenteritis * 0/36 (0.00 %)", "Adverse Events 2:", "Total: 7/13 (53.85 per cent)", "Neutropenia * 2/13 (15.38%)", "Diarrhoea * 0/13 (0.00 %)", "Small intestinal perforation * 1/13 (7.69%)", "* 1/13 (7.69 per cent)", "* 0/13 (0.00 %)", "Fatigue * 0/13 (0.00 %)", "Pain * 0/13 (0.00 %)", "Pyrexia * 0/13 (0.00 %)", "Hypersensitivity * 0/13 (0.00 %)", "* 0/13 (0.00 per cent)", "Gastroenteritis * 1/13 (7.69%)"]}